Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000628549
Ethics application status
Approved
Date submitted
17/04/2024
Date registered
14/05/2024
Date last updated
14/05/2024
Date data sharing statement initially provided
14/05/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Sex differences in skeletal muscle microvascular blood flow in healthy young adults.
Query!
Scientific title
Sex differences in skeletal muscle microvascular blood flow and other cardiovascular responses to acute maximal exercise in healthy young adults.
Query!
Secondary ID [1]
311742
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cardiometabolic diseases
333224
0
Query!
Condition category
Condition code
Cardiovascular
329914
329914
0
0
Query!
Normal development and function of the cardiovascular system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This is a cross-sectional study exploring potential sex differences in cardiovascular responses to a single bout of acute maximal exercise.
Intervention: single graded exercise test on a treadmill (modified Bruce protocol), to assess cardiorespiratory fitness (VO2peak), skeletal muscle microvascular blood flow, femoral artery blood flow, and cardiac responses to acute maximal exercise. Participants will begin walking at 2.7km/h with increasing speed and/or incline every three minutes until exhaustion (see below). VO2peak is calculated from the highest 10-second rolling average of breath-by-breath respiratory gas analysis (Quark RMR Gas Analyzer, Cosmed, Italy). Maximal effort (i.e., adherence to the intervention) will be determined by one or more of the following criteria: a plateau in VO2, heart rate 90% of age-predicted maximum, rating of perceived exertion (RPE) =17, and/or respiratory exchange ratio =1.1.. Electrocardiography will be recorded throughout, with heart rate, blood pressure, and RPE recorded at the end of each 3-minute stage. The testing session will be supervised by a minimum of two first aid trained research staff at Deakin University, Burwood Campus.
Modified Bruce Protocol Stages (3mins each)
Stage 1: 2.7km/h; 0% incline
Stage 2: 2.7km/h; 5% incline
Stage 3: 2.7km/h; 10% incline
Stage 4: 4km/h; 12% incline
Stage 5: 5.5km/h; 14% incline
Stage 6: 6.8km/h; 16% incline
Stage 7: 8km/h; 18% incline
Stage 8: 8.9km/h; 20% incline
Stage 9: 9.7km/h; 22% incline
Pre-intervention testing:
- Questionnaires to collect general health and medical information, menstrual cycle/oral contraceptive use, dietary habits (24 hour diet recall), and physical activity levels (questionnaire and accelerometer worn for 7 days). Participants will be required to wear the accelerometer for all waking hours, except during water-based activities (swimming/bathing). The questionnaires are one-time assessments, each requiring less than 10 minutes to complete. .
- Fasting clinical chemistries (glucose, insulin, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, HbA1c, and female sex hormone concentrations).
- Body composition (height, weight, and lean/fat mass by DEXA).
- Central haemodynamics (systolic and diastolic pressure, pulse pressure, augmentation index, augmentation index at 75bpm, mean arterial pressure) and arterial stiffness assessed via pulse wave analysis and pulse wave velocity.
Query!
Intervention code [1]
328199
0
Treatment: Other
Query!
Comparator / control treatment
Comparator - males
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
337679
0
Skeletal muscle microvascular blood flow responses to acute maximal exercise (composite of microvascular flow velocity and microvascular blood volume).
Query!
Assessment method [1]
337679
0
Contrast-enhanced ultrasound imaging during intravenous infusion of a commercially available contrast agent (Definity, Lantheus Medical Imaging). An L9-3 linear array transducer interfaced to a standard ultrasound machine will be used to image the vastus lateralis (thigh muscle) in cross-section. Depth, gain, and focus will be optimised for each participant and maintained during repeated imaging sequences. A contrast agent suspension (1mL of Definity diluted into 30mL of saline solution) will be infused using a syringe pump. After 4 minutes of infusion at a rate of 42mL/hr to measure Definity concentration in the cross-sectional femoral artery, the infusion rate is increased to 200mL/hr to record real-time video captures of microvascular blood flow in the vastus lateralis. Ultrasound images will be analysed using computer software. The acoustic signal produced by the contrast agent microspheres will be measured and is directly proportional to the number of active/open capillaries and volume of blood within the microvascular system. Following a high-energy ultrasound pulse, all contrast agent microspheres within the ultrasound beam will be destroyed. The rate at which the microspheres reappear provides an indication of microvascular blood velocity. Microvascular blood flow is calculated as the product of microvascular blood volume and blood velocity.
Query!
Timepoint [1]
337679
0
Pre-exercise, immediately after exercise, and 30 minutes post-exercise.
Query!
Secondary outcome [1]
432812
0
Femoral artery blood flow responses to acute maximal exercise (composite of femoral artery diameter and blood velocity).
Query!
Assessment method [1]
432812
0
2D and Doppler ultrasound imaging. Femoral artery diameter and blood velocity will be measured using a commercial ultrasound (Epiq 7, Philips Medical System, North Ryde, NSW, Australia). Diameter (two-dimensional ultrasound) will be recorded at the peak of the QRS complex (determined via three-lead electrocardiography). Blood velocity (pulsed-wave Doppler ultrasound) will be averaged over approximately ten cardiac cycles. Femoral artery mean blood flow (mL/min) is calculated as: pr2 (cm) x mean velocity (cm/s) x 60. Probe location and ultrasound settings will be recorded for repeat measures within visits.
Query!
Timepoint [1]
432812
0
Pre-exercise, 15 minutes post-exercise, and 30 minutes post-exercise.
Query!
Secondary outcome [2]
432813
0
Cardiac index
Query!
Assessment method [2]
432813
0
Echocardiography and three-lead electrocardiography. Two-dimensional and Doppler images will be obtained from the parasternal long axis view and apical four- and five-chamber views. Cardiac output will be calculated by multiplying LV outflow tract (LVOT) area (during peak systole), velocity time integral, and heart rate, indexed to body surface area.
Query!
Timepoint [2]
432813
0
Pre-exercise, immediately after exercise, and 30 minutes post-exercise.
Query!
Secondary outcome [3]
433722
0
Blood glucose
Query!
Assessment method [3]
433722
0
Venous blood collected from an antecubital vein and immediately analysed.
Query!
Timepoint [3]
433722
0
Pre-exercise, 15 minutes post-exercise, 30 minutes post-exercise
Query!
Secondary outcome [4]
433723
0
Blood lactate
Query!
Assessment method [4]
433723
0
Venous blood collected from an antecubital vein and immediately analysed.
Query!
Timepoint [4]
433723
0
Pre-exercise, 15 minutes post-exercise, and 30 minutes post-exercise
Query!
Eligibility
Key inclusion criteria
Body mass index 18.5-30kg/m2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
45
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Diagnosis of insulin resistance/diabetes or cardiovascular disease; uncontrolled hypertension (brachial blood pressure >160/100mmHg); known liver/kidney disease; current or previous cancer; physical limitations to exercise; current or past smoker (12 months); currently engaging in >300mins/week of moderate to vigorous physical activity; pregnancy/lactation; irregular menstrual cycle; use of non-monophasic oral contraceptive pill; oral contraceptive pill use for non-contraceptive purposes; females who are peri- or post-menopausal; a previous reaction to Definity contrast agent.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/06/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
34
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
316074
0
University
Query!
Name [1]
316074
0
Deakin University HDR funds
Query!
Address [1]
316074
0
Query!
Country [1]
316074
0
Australia
Query!
Funding source category [2]
316075
0
University
Query!
Name [2]
316075
0
Deakin University Alfred Deakin Postdoctoral Research Fellowship
Query!
Address [2]
316075
0
Query!
Country [2]
316075
0
Australia
Query!
Primary sponsor type
University
Query!
Name
Deakin University
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
318241
0
None
Query!
Name [1]
318241
0
Query!
Address [1]
318241
0
Query!
Country [1]
318241
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
314893
0
Deakin University Human Research Ethics Committee (DUHREC)
Query!
Ethics committee address [1]
314893
0
Deakin University Melbourne Campus, 221 Burwood Highway, Burwood, Victoria, 3125
Query!
Ethics committee country [1]
314893
0
Australia
Query!
Date submitted for ethics approval [1]
314893
0
05/03/2024
Query!
Approval date [1]
314893
0
13/05/2024
Query!
Ethics approval number [1]
314893
0
Query!
Summary
Brief summary
This study will explore potential sex differences in skeletal muscle microvascular blood flow and other cardiovascular responses to acute maximal exercise in 34 healthy young adults (17 premenopausal females and 17 age-matched males). Microvascular blood flow will be assessed via contrast-enhanced ultrasound at rest, immediately after, and 30 minutes after completing a maximal graded exercise test. Additional assessments include heart and large artery function, body composition, physical activity levels, and blood sampling for biomarkers associated with cardiometabolic health. We hypothesise that healthy premenopausal females will have larger skeletal muscle microvascular blood flow responses to acute maximal exercise than age-matched males, reflecting their known greater vasodilatory responses in large arteries. Findings will inform sex-specific cardiovascular risk factors, and aid in the development of early detection strategies and more targeted prevention and management approaches.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
133074
0
Dr Kimberley Way
Query!
Address
133074
0
Deakin University, 221 Burwood Highway, Burwood, VIC, 3125
Query!
Country
133074
0
Australia
Query!
Phone
133074
0
+61 3 924 68894
Query!
Fax
133074
0
Query!
Email
133074
0
[email protected]
Query!
Contact person for public queries
Name
133075
0
Kimberley Way
Query!
Address
133075
0
Deakin University, 221 Burwood Highway, Burwood, VIC, 3125
Query!
Country
133075
0
Australia
Query!
Phone
133075
0
+61 3 924 68894
Query!
Fax
133075
0
Query!
Email
133075
0
[email protected]
Query!
Contact person for scientific queries
Name
133076
0
Kimberley Way
Query!
Address
133076
0
Deakin University, 221 Burwood Highway, Burwood, VIC, 3125
Query!
Country
133076
0
Australia
Query!
Phone
133076
0
+61 3 924 68894
Query!
Fax
133076
0
Query!
Email
133076
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Due to confidentiality data will not be shared.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
21989
Ethical approval
387504-(Uploaded-14-05-2024-14-49-51)-Study-related document.pdf
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF